Cancer Biomarker Research and Personalized Medicine

Biomarkers are measures of a biological state. The treatment of individual patients based on particular factors, such as biomarkers, distinguishes standard, generalized treatment plans from personalized medicine. Even though personalized medicine is applicable to most branches of medicine, the field...

Full description

Saved in:
Bibliographic Details
Sonstige:
Year of Publication:2022
Language:English
Physical Description:1 electronic resource (428 p.)
Tags: Add Tag
No Tags, Be the first to tag this record!
LEADER 04963nam-a2201333z--4500
001 993600375204498
005 20231214132952.0
006 m o d
007 cr|mn|---annan
008 202205s2022 xx |||||o ||| 0|eng d
035 |a (CKB)5680000000037538 
035 |a (oapen)https://directory.doabooks.org/handle/20.500.12854/81000 
035 |a (EXLCZ)995680000000037538 
041 0 |a eng 
100 1 |a Meehan, James  |4 edt 
245 1 0 |a Cancer Biomarker Research and Personalized Medicine 
260 |a Basel  |b MDPI - Multidisciplinary Digital Publishing Institute  |c 2022 
300 |a 1 electronic resource (428 p.) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
520 |a Biomarkers are measures of a biological state. The treatment of individual patients based on particular factors, such as biomarkers, distinguishes standard, generalized treatment plans from personalized medicine. Even though personalized medicine is applicable to most branches of medicine, the field of oncology is perhaps where it is most easily employed. Cancer is a heterogeneous disease; although patients may be diagnosed histologically with the same cancer type, their tumors can comprise varying tumor microenvironments and molecular characteristics that can impact treatment response and prognosis. There has been a major drive over the past decade to try and realize personalized cancer medicine through the discovery and use of disease-specific biomarkers. This book, entitled “Cancer Biomarker Research and Personalized Medicine”, encompasses 22 publications from colleagues working on a diverse range of cancers, including prostate, breast, ovarian, head and neck, liver, gastric, bladder, colorectal, and kidney. The biomarkers assessed in these studies include genes, intracellular or secreted proteins, exosomes, DNA, RNA, miRNA, circulating tumor cells, circulating immune cells, in addition to radiomic features. 
546 |a English 
650 7 |a Medicine  |2 bicssc 
650 7 |a Oncology  |2 bicssc 
653 |a clear cell renal cell carcinoma 
653 |a radiomics 
653 |a WHO/ISUP nuclear grade 
653 |a multiphasic multidetector computed tomography 
653 |a triple-negative breast cancer 
653 |a taxane 
653 |a chemotherapy 
653 |a GBP5 
653 |a Akt/mTOR 
653 |a autophagy 
653 |a IL13Rα2 
653 |a renal cell carcinoma 
653 |a JAK2 
653 |a FOXO3 
653 |a telmisartan 
653 |a ovarian cancer 
653 |a bioinformatics 
653 |a CREB1 
653 |a drug perturbation 
653 |a lincRNA-p21 
653 |a rectal cancer 
653 |a chemoradiotherapy 
653 |a colorectal cancer 
653 |a long non-coding RNA 
653 |a p53 
653 |a predictive biomarker 
653 |a intestinal anastomosis 
653 |a anastomotic leak 
653 |a biomarkers 
653 |a precision medicine 
653 |a personalized medicine 
653 |a biomarker 
653 |a AmpliSeq 
653 |a DNA methylation 
653 |a epigenetics 
653 |a head and neck cancer 
653 |a saliva 
653 |a liquid biopsy 
653 |a meta-analysis 
653 |a gastric cancer 
653 |a middle-up-down 
653 |a haptoglobin 
653 |a glycopeptide 
653 |a mass spectrometry 
653 |a circulating tumor cells 
653 |a prostate cancer 
653 |a cancer vaccine 
653 |a immune response 
653 |a breast cancer 
653 |a predictive tools 
653 |a prognostic tools 
653 |a translational research 
653 |a IL6ST 
653 |a gp130 
653 |a cytokine signalling 
653 |a tissue-based biomarkers 
653 |a liquid-based biomarkers 
653 |a radiotherapy 
653 |a radiosensitivity biomarkers 
653 |a secretome 
653 |a radioresistance 
653 |a bladder tumor 
653 |a lymphocyte-to-monocyte ratio 
653 |a peripheral blood parameters 
653 |a tumor recurrence 
653 |a transurethral resection 
653 |a lipidomics 
653 |a 1H-NMR 
653 |a LC-MS/MS 
653 |a lipoprotein subfractions 
653 |a lipoprotein lipase 
653 |a cancer biomarkers 
653 |a hepatocellular carcinoma 
653 |a p16 expression 
653 |a head and neck squamous cell carcinoma 
653 |a HPV genotyping 
653 |a exosomes 
653 |a chemoresistance 
653 |a comparative oncology 
653 |a One Health 
653 |a microRNA 
653 |a lymph node metastasis 
653 |a hormone-dependent carcinogenesis 
653 |a localized prostate cancer 
653 |a prognostic factors 
653 |a HNSCC 
776 |z 3-0365-3918-2 
776 |z 3-0365-3917-4 
700 1 |a Meehan, James  |4 oth 
906 |a BOOK 
ADM |b 2023-12-15 05:38:35 Europe/Vienna  |f system  |c marc21  |a 2022-05-14 21:41:54 Europe/Vienna  |g false 
AVE |i DOAB Directory of Open Access Books  |P DOAB Directory of Open Access Books  |x https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5345742530004498&Force_direct=true  |Z 5345742530004498  |b Available  |8 5345742530004498